Boehringer Ingelheim will collaborate with Weill Cornell Medicine to identify new treatment approaches for COPD. The partnership aims to develop novel treatments that could possibly halt or even reverse the progression of the disease process, according to a press announcement from Boehringer.
The new, three-year collaboration combines Weill Cornell Medicine’s Department of Genetic Medicine’s unique understanding of chronic airway diseases and experience in the investigation of novel therapeutic concepts for airway repair with Boehringer Ingelheim’s expertise in the discovery and development of new therapies for respiratory diseases.
“Our continuous search for molecular drivers of chronic obstructive airway diseases has revealed novel repair mechanisms that warrant further investigation of their potential as therapeutic approaches,” said Dr. Ronald G. Crystal, Chairman of Genetic Medicine at Weill Cornell Medicine and lead investigator in the new collaboration. “We will look to further expand our knowledge about progressive airway destruction in close collaboration with Boehringer Ingelheim and focus on promising therapeutic concepts with the potential to slow down or halt progressive airway damage in patients with COPD.”
This collaboration is the second collaboration between Boehringer Ingelheim and Weill Cornell Medicine, following prior work in inflammatory bowel disease (IBD).
